Henry Chang
机构：AbbVie (United States)
发表论文 2 篇
代表论文
- A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA–positive colorectal cancer. (2026 · Journal of Clinical Oncology)
- A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer. (2026 · Journal of Clinical Oncology)